Title: Daedeok-net– LegoChem, selected as Korea Drug Development Fund Company

Publication: Daedeok-net / Ae Kyung Kil

Date: 05 March 2012

Summary

• LegoChem Bioscience’s Oxazolidinone antibiotics LCB01-0371 was selected for ‘Korea Drug Development Fund’, which supports 50% of developing cost for next 17 months. With the required funding secured, LegoChem started the clinical study phase 1 at Seoul Asan Hospital on March.

• Oxazolidinone antibiotics LCB01-0371 treats respiratory and skin infections caused by Gram-positive cocci such as MRSA and VRE. LegoChem developed the antibiotics to be highly soluble so that they can be used both in pills and injections. Also, LCB01-0371 can be administered only once a day.

• CEO Dr. Yong Zu Kim was selected as a representative speaker of Oxazolidinone medicine in the world’s largest Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) held in Chicago, USA last year, so he gave a presentation about Oxazolidinone antibiotics.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).